[Bronchospasmolysis with Atroven (SCH 1.000) (author's transl)].
A study was performed to evaluate the influence of Atrovent (SCH 1.000) and Ephedrine on the bronchial resistance in patients with obstructive airway diseases. The inhalation of SCH 1.000 was followed by a significant decrease in resistance reaching a maximum of 49.1% and lasting for four hours post inhalation. Ephedrine tablets were comparatively less effective. The second part of our study concerns the cardiovascular reaction of patients with coronary artery diseases after inhalation of SCH 1.000. Side effects involving the cardiovascular system due to inhalation therapy with SCH 1.000 were not registered. Atrovent is recommended as an excellent bronchodilator drug especially in patients with underlying coronary artery disease or tachycardial arrhythmias.
D000403:Airway Resistance / Q000187:drug effects; D001285:Atropine / Q000009:adverse effects / Q000627:therapeutic use*; D001986:Bronchial Spasm / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications; D004338:Drug Combinations; D004809:Ephedrine / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D009921:Metaproterenol / Q000494:pharmacology; D008875:Middle Aged; D010919:Placebos; D012129:Respiratory Function Tests
D001993:Bronchodilator Agents; D004338:Drug Combinations; D010919:Placebos; D009921:Metaproterenol; D001285:Atropine; D004809:Ephedrine
Bronchospasmolyse mit Atrovent